Search
Lipocine Inc
LPCNAdd to Watchlist
2.390USD
-0.070-2.85%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
17.87MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-2.85%
5 Days
-2.85%
1 Month
+8.14%
6 Months
-70.13%
Year to Date
-70.24%
1 Year
-22.90%
Key Figures
2.450Open
2.450High
66.85KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.89%Turnover Ratio
2.460Prev. Close
2.380Low
110.73KTurnover
2139.07P/E Static
0.78P/B
0.00%Div Yield TTM
-49.87%ROA
12.37052wk High
2.10Volume Ratio
8.35KNet Profit
7.48MShares
-1.9586EPS TTM
1.10Beta
-54.41%ROE
2.52052wk Low
2.85%Amplitude
100.00%Gross Margin
17.87MMarket Cap
2.50Reward/Risk
4.52%Risk Rate
TradingKey Stock Score of Lipocine Inc
Currency: USD Updated: 2026-07-02Key Insights
Lipocine Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 146 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 6.00.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Lipocine Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Lipocine Inc Highlights
StrengthsRisks
Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics. The Company’s clinical development candidates include: LPCN 1154, oral brexanolone, for the treatment of postpartum depression, LPCN 2101, for the treatment of epilepsy, LPCN 2203, an oral candidate targeted for the management of essential tremor, LPCN 2401, an oral proprietary anabolic androgen receptor agonist for improved body composition in obesity management, and LPCN 1148, for the management of decompensated cirrhosis. It is also developing LPCN 1107, for the prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, and LPCN 1144, for the treatment of metabolic dysfunction-associated steatohepatitis. Its product candidate, TLANDO, is a novel oral prodrug of testosterone containing testosterone undecanoate developed by the Company.
Growing
The company is in a growing phase, with the latest annual income totaling USD 1.98M.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Overvalued
The company’s latest PE is -1.22, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 2.08M shares, increasing 42.40% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.08.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
6.000
Target Price
+143.90%
Upside Space
Lipocine Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Lipocine Inc Info
Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics. The Company’s clinical development candidates include: LPCN 1154, oral brexanolone, for the treatment of postpartum depression, LPCN 2101, for the treatment of epilepsy, LPCN 2203, an oral candidate targeted for the management of essential tremor, LPCN 2401, an oral proprietary anabolic androgen receptor agonist for improved body composition in obesity management, and LPCN 1148, for the management of decompensated cirrhosis. It is also developing LPCN 1107, for the prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, and LPCN 1144, for the treatment of metabolic dysfunction-associated steatohepatitis. Its product candidate, TLANDO, is a novel oral prodrug of testosterone containing testosterone undecanoate developed by the Company.
Ticker SymbolLPCN
CompanyLipocine Inc
CEOPatel (Mahesh V)
Websitehttps://www.lipocine.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Lipocine Inc (LPCN)?
The current price of Lipocine Inc (LPCN) is 2.39.
What is the symbol of Lipocine Inc?
The ticker symbol of Lipocine Inc is LPCN.
What is the 52-week high of Lipocine Inc?
The 52-week high of Lipocine Inc is 12.37.
What is the 52-week low of Lipocine Inc?
The 52-week low of Lipocine Inc is 2.52.
What is the market capitalization of Lipocine Inc?
The market capitalization of Lipocine Inc is 17.87M.
Is Lipocine Inc (LPCN) currently rated as Buy, Hold, or Sell?
According to analysts, Lipocine Inc (LPCN) has an overall rating of Buy, with a price target of 6.00.
What is the Earnings Per Share (EPS TTM) of Lipocine Inc (LPCN)?
The Earnings Per Share (EPS TTM) of Lipocine Inc (LPCN) is -1.77.